ストックスクリーナーアプリを入手
0.00
100.00%
-6.75
Athira Pharma Inc (ATHA) 最新ニュース
Athira Pharma (LONA) FDA Approvals, PDUFA Dates & Drug Alerts 2026 $LONA - MarketBeat
Independent Nonclinical Research on Lasofoxifene Presented - GlobeNewswire
Athira Pharma (NASDAQ:LONA) Shares Down 6.5%Should You Sell? - MarketBeat
28,000-share stock option grant to LeonaBio (LONA) director - Stock Titan
LeonaBio (LONA) awards 300,000 stock options to chief scientific officer - Stock Titan
28,000 stock options granted to LeonaBio (LONA) director Kosacz - Stock Titan
LeonaBio (LONA) director Grant Pickering receives 28,000 stock options - Stock Titan
Director Romano Kelly receives 28,000 LeonaBio (LONA) stock options at $9.54 - Stock Titan
LeonaBio (LONA) director receives options to buy 28,000 shares at $9.54 - Stock Titan
LeonaBio (LONA) director awarded options on 28,000 shares at $9.54 - Stock Titan
LeonaBio (LONA) grants CMO 350,000 options at $9.54 - Stock Titan
Director John M. Fluke Jr. receives 28,000-share option grant at LeonaBio (LONA) - Stock Titan
LeonaBio (LONA) awards 300,000 stock options to general counsel - Stock Titan
LeonaBio (LONA) CFO awarded 300,000 stock options at $9.54 - Stock Titan
LeonaBio (LONA) CEO awarded 750,000 stock options at $9.54 strike - Stock Titan
Sentiment Recap: Should I invest in Athira Pharma Inc before earningsQuarterly Portfolio Summary & Breakout Confirmation Alerts - baoquankhu1.vn
Market Outlook: What is the long term forecast for Athira Pharma Inc stockNew Guidance & Reliable Trade Execution Plans - baoquankhu1.vn
Top Athira Pharma (LONA) Competitors 2026 - MarketBeat
Athira Pharma, Inc. (LONA) Stock Forecast & Price Prediction 2026–2030 - CoinCodex
Mizuho raises LeonaBio stock price target to $16 on breast cancer drug outlook - Investing.com
Athira Pharma, Inc. (ATHA) Competitors - Meyka
[EFFECT] LeonaBio, Inc. SEC Filing - Stock Titan
Performance Recap: What is the PEG ratio of Athira Pharma Inc2026 Catalysts & Trade Opportunity Analysis Reports - baoquankhu1.vn
LeonaBio (NASDAQ: ATHA) registers 58.5M shares; warrants could yield $146M - Stock Titan
RSI Check: Is Athira Pharma Incs growth already priced in2026 Gainers & Reliable Price Action Trade Plans - baoquankhu1.vn
LeonaBio (ATHA) clears resale of 5.5M warrant shares for Sermonix - Stock Titan
LeonaBio (NASDAQ: LONA) files resale registration for PIPE warrant holders - Stock Titan
LeonaBio (NASDAQ: ATHA) expands Sermonix deal disclosure and ELAINE-3 trial spend - Stock Titan
Income Plays: Can Athira Pharma Inc be recession proofEarnings Risk Report & Reliable Trade Execution Plans - baoquankhu1.vn
Aug Movers: Can Athira Pharma Inc expand into new markets2026 Market Trends & Weekly Market Pulse Alerts - baoquankhu1.vn
LeonaBio Reports 2025 Financial Results, Acquires Lasofoxifene License, and Advances Clinical Pipeline for Metastatic Breast Cancer and ALS 123 - Minichart
LeonaBio Updates Investors on 2025 Results and Strategy - TipRanks
LeonaBio Reports Full Year 2025 Financial Results and Provides Business Update - Bitget
LeonaBio (NASDAQ: LONA) boosts cash to fund Phase 3 breast cancer drug - Stock Titan
Momentum Shift: Can Athira Pharma Inc be recession proof2026 Pullback Review & Low Risk High Win Rate Picks - baoquankhu1.vn
Contrasting Athira Pharma (NASDAQ:LONA) & Prime Medicine (NASDAQ:PRME) - Defense World
What dividend growth rate does Athira Pharma Inc offer2026 Short Interest & Accurate Intraday Trading Signals - baoquankhu1.vn
LeonaBio shareholders approve equity plan and increase in authorized shares - Investing.com India
LeonaBio (ATHA) wins approval for 2026 equity plan and major share increase - Stock Titan
Published on: 2026-03-20 02:58:44 - baoquankhu1.vn
Risk Report: Can Athira Pharma Inc ride the EV wave2026 Macro Impact & Advanced Swing Trade Entry Alerts - baoquankhu1.vn
Earnings Miss: Is Athira Pharma Inc subject to activist investor interest2026 Trading Volume Trends & Trade Opportunity Analysis Reports - baoquankhu1.vn
Athira Pharma shares surge after securing rights to phase 3 breast cancer therapy - MSN
Shorts Report: Can Athira Pharma Inc be recession proofEarnings Risk Summary & Real-Time Volume Trigger Notifications - baoquankhu1.vn
[DEFR14A] LeonaBio, Inc. Revised Proxy Statement - Stock Titan
Reviewing Athira Pharma (NASDAQ:LONA) and Inhibikase Therapeutics (NASDAQ:IKT) - Defense World
Reviewing Athira Pharma (NASDAQ:LONA) and Liminatus Pharma (NASDAQ:LIMN) - Defense World
Sentiment Review: Is Athira Pharma Inc subject to activist investor interest2025 Earnings Surprises & Low Risk Entry Point Tips - baoquankhu1.vn
Should I invest in Athira Pharma Inc before earningsPortfolio Risk Report & Weekly Setup with High ROI Potential - baoquankhu1.vn
LeonaBio CEO Litton sells $27,687 in shares By Investing.com - Investing.com India
LeonaBio CEO Litton sells $27,687 in shares - Investing.com South Africa
Renninger, LeonaBio CFO, sells $4.9k in LONA stock - Investing.com Australia
LeonaBio (ATHA) counsel sells 1,328 shares to cover RSU tax bill - Stock Titan
4.95%
大文字化:
|
ボリューム (24 時間):